{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:12:55Z","timestamp":1794276775425,"version":"4.9.0"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Retinal and Eye Research"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.preteyeres.2024.101302","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T02:16:22Z","timestamp":1726712182000},"page":"101302","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Ocular adverse events associated with antibody-drug conjugates used in cancer: Focus on pathophysiology and management strategies"],"prefix":"10.1016","volume":"103","author":[{"given":"Eric E.","family":"Gabison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Labetoulle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Gazzah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Besse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.preteyeres.2024.101302_bib1","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/bjh.18298","article-title":"Impact of belantamab mafodotin-induced ocular toxicity on outcomes of patients with advanced multiple myeloma","volume":"199","author":"Abeykoon","year":"2022","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.preteyeres.2024.101302_bib2","article-title":"Zynlonta\u2122 (loncastuximab tesirine-lpyl) for injection, for intravenous use","year":"2022","journal-title":"Prescribing information. ADC Therapeutics SA"},{"key":"10.1016\/j.preteyeres.2024.101302_bib3","series-title":"Prescribing Information","article-title":"PadcevTM (enfortumab vedotin-ejfv) for injection, for intravenous use","author":"Seagen Inc","year":"2023"},{"key":"10.1016\/j.preteyeres.2024.101302_bib4","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1634\/theoncologist.2019-0025","article-title":"The EMA review of Mylotarg (gemtuzumab ozogamicin) for the treatment of acute myeloid leukemia","volume":"24","author":"Ali","year":"2019","journal-title":"Oncol."},{"key":"10.1016\/j.preteyeres.2024.101302_bib5","first-page":"63","article-title":"Tissue factor expression in human pterygium","volume":"17","author":"Ando","year":"2011","journal-title":"Mol. Vis."},{"key":"10.1016\/j.preteyeres.2024.101302_bib6","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ajo.2022.06.009","article-title":"Corneal toxicity associated with belantamab mafodotin is not restricted to the epithelium: neuropathy studied with confocal microscopy","volume":"242","author":"Aschauer","year":"2022","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2024.101302_bib7","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s10792-022-02527-8","article-title":"Vision-related quality of life amongst patients with low vision and blindness in a resource-limited country","volume":"43","author":"Asimadu","year":"2023","journal-title":"Int. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2024.101302_bib8","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S1470-2045(19)30328-6","article-title":"Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study","volume":"20","author":"Banerji","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.preteyeres.2024.101302_bib9","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody\u2013drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.preteyeres.2024.101302_bib10","doi-asserted-by":"crossref","first-page":"5733","DOI":"10.1002\/cncr.27622","article-title":"A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer","volume":"118","author":"Beeram","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.preteyeres.2024.101302_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2021.115534","article-title":"Microtubule and tubulin binding and regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload, monomethyl auristatin E (MMAE): mechanistic insights into MMAE ADC peripheral neuropathy","volume":"421","author":"Best","year":"2021","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.preteyeres.2024.101302_bib12","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/stem.5530130408","article-title":"Mechanism of action of DNA topoisomerase inhibitors","volume":"13","author":"Binaschi","year":"1995","journal-title":"Stem Cell."},{"key":"10.1016\/j.preteyeres.2024.101302_bib13","doi-asserted-by":"crossref","first-page":"6","DOI":"10.36401\/JIPO-20-21","article-title":"Targeted cancer therapy and its ophthalmic side effects: a review","volume":"4","author":"Bindiganavile","year":"2021","journal-title":"J. Immunother. Precis. Oncol."},{"key":"10.1016\/j.preteyeres.2024.101302_bib14","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1167\/iovs.07-0430","article-title":"Functions of MUC16 in corneal epithelial cells","volume":"48","author":"Blalock","year":"2007","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2024.101302_bib15","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1158\/1078-0432.CCR-21-3656","article-title":"Praluzatamab ravtansine, a CD166-targeting antibody-drug conjugate, in patients with advanced solid tumors: an open-label phase I\/II trial","volume":"28","author":"Boni","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.preteyeres.2024.101302_bib16","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1021\/acs.molpharmaceut.6b00082","article-title":"Increment in drug loading on an antibody-drug conjugate increases its binding to the human neonatal Fc receptor in vitro","volume":"13","author":"Brachet","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.preteyeres.2024.101302_bib17","doi-asserted-by":"crossref","DOI":"10.1001\/jamaophthalmol.2022.3226","article-title":"Chemotherapy-induced hyperopic surprise in a woman with multiple myeloma","volume":"140","author":"Bui","year":"2022","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.preteyeres.2024.101302_bib18","doi-asserted-by":"crossref","first-page":"5781","DOI":"10.1158\/1078-0432.CCR-21-0765","article-title":"Phase I study of 2- or 3-week dosing of telisotuzumab vedotin, an antibody-drug conjugate targeting c-Met, monotherapy in patients with advanced non-small cell lung carcinoma","volume":"27","author":"Camidge","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.preteyeres.2024.101302_bib19","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1097\/ICO.0000000000002934","article-title":"Refractive shifts and changes in corneal curvature associated with antibody-drug conjugates","volume":"41","author":"Canestraro","year":"2022","journal-title":"Cornea"},{"key":"10.1016\/j.preteyeres.2024.101302_bib20","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/bjh.13992","article-title":"A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"173","author":"Coiffier","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.preteyeres.2024.101302_bib21","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.preteyeres.2024.101302_bib22","article-title":"Enhertu. Prescribing information","year":"2022","journal-title":"Daiichi Sankyo, Inc."},{"key":"10.1016\/j.preteyeres.2024.101302_bib23","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1023\/A:1008060720608","article-title":"Mechanisms of resistance to alkylating agents","volume":"27","author":"Damia","year":"1998","journal-title":"Cytotechnology"},{"key":"10.1016\/j.preteyeres.2024.101302_bib24","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1188\/16.ONF.235-243","article-title":"Ocular toxicity of tyrosine kinase inhibitors","volume":"43","author":"Davis","year":"2016","journal-title":"Oncol. Nurs. Forum"},{"key":"10.1016\/j.preteyeres.2024.101302_bib25","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1470-2045(18)30859-3","article-title":"Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial","volume":"20","author":"de Bono","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.preteyeres.2024.101302_bib26","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s10549-019-05179-y","article-title":"Corneal features in trastuzumab emtansine treatment: not a rare occurrence","volume":"175","author":"Deklerck","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.preteyeres.2024.101302_bib27","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1007\/s12094-023-03261-y","article-title":"Adverse events of antibody-drug conjugates on the ocular surface in cancer therapy","volume":"25","author":"Dom\u00ednguez-Llamas","year":"2023","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.preteyeres.2024.101302_bib28","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/19420862.2016.1156829","article-title":"Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates","volume":"8","author":"Donaghy","year":"2016","journal-title":"mAbs"},{"key":"10.1016\/j.preteyeres.2024.101302_bib29","series-title":"Ocular Surface Epithelium: Applied Anatomy","first-page":"175","author":"Dua","year":"2019"},{"key":"10.1016\/j.preteyeres.2024.101302_bib30","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/jop.2015.0064","article-title":"Ocular adverse events associated with antibody-drug conjugates in human clinical trials","volume":"31","author":"Eaton","year":"2015","journal-title":"J. Ocul. Pharmacol. Therapeut."},{"key":"10.1016\/j.preteyeres.2024.101302_bib39","first-page":"889","article-title":"Corneal epithelial findings in patients with multiple myeloma treated with antibody-drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 study. Ophthalmol","volume":"9","author":"Farooq","year":"2020","journal-title":"Ther"},{"key":"10.1016\/j.preteyeres.2024.101302_bib40","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40265-021-01507-z","article-title":"Ocular toxicity of targeted anticancer agents","volume":"81","author":"Fortes","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.preteyeres.2024.101302_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23062997","article-title":"An experimental model of neuro-immune interactions in the eye: corneal sensory nerves and resident dendritic cells","volume":"23","author":"Frutos-Rinc\u00f3n","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.preteyeres.2024.101302_bib42","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.annonc.2021.12.012","article-title":"Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study","volume":"33","author":"Gazzah","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.preteyeres.2024.101302_bib43","article-title":"Kadcyla\u00ae (ado-trastuzumab emtansine) for injection, for intravenous use","year":"2022","journal-title":"Prescribing information. Genentech, Inc."},{"key":"10.1016\/j.preteyeres.2024.101302_bib44","article-title":"Polivy\u2122 (polatuzumab vedotin-piiq) for injection, for intravenous use","year":"2023","journal-title":"Prescribing information. Genentech, Inc"},{"key":"10.1016\/j.preteyeres.2024.101302_bib45","article-title":"TrodelvyTM (sacituzumab govitecan-hziy) for injection, for intravenous use","year":"2023","journal-title":"Prescribing information. Gilead Sciences, Inc."},{"key":"10.1016\/j.preteyeres.2024.101302_bib46","doi-asserted-by":"crossref","first-page":"764","DOI":"10.2174\/13892002113149990099","article-title":"Neonatal Fc receptor and its role in the absorption, distribution, metabolism and excretion of immunoglobulin G-based biotherapeutics","volume":"14","author":"Giragossian","year":"2013","journal-title":"Curr. Drug Metabol."},{"key":"10.1016\/j.preteyeres.2024.101302_bib47","article-title":"Blenrep (belantamab mafodotin-blmf) injection, for intravenous use","year":"2022","journal-title":"Prescribing information. GlaxoSmithKline"},{"key":"10.1016\/j.preteyeres.2024.101302_bib48","article-title":"ElahereTM (mirvetuximab soravtansine-gynx) injection, for intravenous use","year":"2022","journal-title":"Prescribing information. ImmunoGen, Inc."},{"key":"10.1016\/j.preteyeres.2024.101302_bib49","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.clml.2019.02.006","article-title":"Indatuximab ravtansine (BT062) monotherapy in patients with relapsed and\/or refractory multiple myeloma","volume":"19","author":"Jagannath","year":"2019","journal-title":"Clin. Lymphoma, Myeloma & Leukemia"},{"key":"10.1016\/j.preteyeres.2024.101302_bib50","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1158\/2159-8290.CD-21-0715","article-title":"Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer","volume":"12","author":"J\u00e4nne","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.preteyeres.2024.101302_bib51","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1158\/1078-0432.CCR-21-0194","article-title":"Phase I, first-in-human study of the Probody therapeutic CX-2029 in adults with advanced solid tumor malignancies","volume":"27","author":"Johnson","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.preteyeres.2024.101302_bib52","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.clml.2015.12.004","article-title":"A phase II study of coltuximab ravtansine (SAR3419) monotherapy in patients with relapsed or refractory acute lymphoblastic leukemia","volume":"16","author":"Kantarjian","year":"2016","journal-title":"Clin. Lymphoma, Myeloma & Leukemia"},{"key":"10.1016\/j.preteyeres.2024.101302_bib53","doi-asserted-by":"crossref","first-page":"e794","DOI":"10.1016\/S2352-3026(21)00208-8","article-title":"Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1\/2a study","volume":"8","author":"Kelly","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.preteyeres.2024.101302_bib54","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ygyno.2022.02.010","article-title":"Mitigation and management strategies for ocular events associated with tisotumab vedotin","volume":"165","author":"Kim","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.preteyeres.2024.101302_bib55","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S1470-2045(22)00061-4","article-title":"Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial","volume":"23","author":"Kindler","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.preteyeres.2024.101302_bib56","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.3390\/pharmaceutics15082160","article-title":"Antibody-drug conjugates in solid tumor oncology: an effectiveness payday with a targeted payload","volume":"15","author":"Kondrashov","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.preteyeres.2024.101302_bib57","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS21-GS1-05","article-title":"Datopotamab deruxtecan in advanced\/metastatic HER2- breast cancer: results from the phase 1 TROPION-PanTumor01 study","volume":"82","author":"Krop","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.preteyeres.2024.101302_bib58","doi-asserted-by":"crossref","DOI":"10.3390\/membranes10080177","article-title":"Macropinocytosis in different cell types: similarities and differences","volume":"10","author":"Lin","year":"2020","journal-title":"Membranes"},{"key":"10.1016\/j.preteyeres.2024.101302_bib59","article-title":"Ocular side effects of systemically administered chemotherapy, UpToDate","author":"Liu","year":"2023","journal-title":"Wolters Kluwer"},{"key":"10.1016\/j.preteyeres.2024.101302_bib60","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ygyno.2021.09.023","article-title":"An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer","volume":"163","author":"Liu","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.preteyeres.2024.101302_bib61","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.preteyeres.2024.101302_bib62","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41408-021-00494-4","article-title":"Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)","volume":"11","author":"Lonial","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.preteyeres.2024.101302_bib63","article-title":"ELU-FR\u03b1-1: a study to evaluate ELU001 in patients with solid tumors that overexpress folate receptor alpha (FR\u03b1)","volume":"40","author":"Ma","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.preteyeres.2024.101302_bib64","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.pharmthera.2019.04.008","article-title":"Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates","volume":"200","author":"Mahalingaiah","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.preteyeres.2024.101302_bib65","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1158\/1078-0432.CCR-20-3757","article-title":"First-in-human study of PF-06647020 (cofetuzumab pelidotin), an antibody-drug conjugate targeting protein tyrosine kinase 7, in advanced solid tumors","volume":"27","author":"Maitland","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.preteyeres.2024.101302_bib66","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1001\/archopht.119.7.1050","article-title":"Development of the 25-item national eye Institute visual function questionnaire","volume":"119","author":"Mangione","year":"2001","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2024.101302_bib67","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.lungcan.2021.11.016","article-title":"Antibody drug conjugates in non-small cell lung cancer: an emerging therapeutic approach","volume":"163","author":"Marks","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.preteyeres.2024.101302_bib68","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/17469899.2023.2281448","article-title":"Improving access to eye care in low and middle-income countries \u2013 challenges, opportunities, and the way forward","volume":"18","author":"Marmamula","year":"2023","journal-title":"Expet Rev. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2024.101302_bib69","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.pharmthera.2016.03.007","article-title":"A comprehensive review of the neonatal Fc receptor and its application in drug delivery","volume":"161","author":"Martins","year":"2016","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.preteyeres.2024.101302_bib70","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1158\/1078-0432.CCR-18-2474","article-title":"Evaluation of prophylactic corticosteroid eye drop use in the management of corneal abnormalities induced by the antibody-drug conjugate mirvetuximab soravtansine","volume":"25","author":"Matulonis","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.preteyeres.2024.101302_bib71","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.5512","article-title":"Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FR\u03b1) expression: characterization of antitumor activity in the SORAYA study","volume":"40","author":"Matulonis","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.preteyeres.2024.101302_bib72","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.preteyeres.2024.101302_bib73","doi-asserted-by":"crossref","first-page":"E451","DOI":"10.1002\/ajh.26728","article-title":"Corneal toxicity with belantamab mafodotin: multi-institutional real-life experience","volume":"97","author":"Mohan","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.preteyeres.2024.101302_bib74","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","article-title":"Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I","volume":"32","author":"Moore","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.preteyeres.2024.101302_bib76","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1007\/s00018-010-0572-7","article-title":"Expression and distribution of immunoglobulin G and its receptors in an immune privileged site: the eye","volume":"68","author":"Niu","year":"2011","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.preteyeres.2024.101302_bib77","article-title":"Acute keratoconjunctivitis associated with tisotumab vedotin-tftv for metastatic cervical cancer","volume":"33","author":"Parikh","year":"2024","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.preteyeres.2024.101302_bib78","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.593461","article-title":"Ocular side effects of EGFR-inhibitor ABT-414 in recurrent glioblastoma: a long-term safety study","volume":"10","author":"Parrozzani","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.preteyeres.2024.101302_bib79","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1158\/1535-7163.MCT-16-0641","article-title":"Modulating therapeutic activity and toxicity of pyrrolobenzodiazepine antibody-drug conjugates with self-immolative disulfide linkers","volume":"16","author":"Pillow","year":"2017","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.preteyeres.2024.101302_bib80","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1182\/blood-2020-140013","article-title":"DREAMM-2: single-agent belantamab mafodotin (Belamaf) effects on patient-reported outcome (PRO) measures in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"136","author":"Popat","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.preteyeres.2024.101302_bib81","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.preteyeres.2024.101302_bib82","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1167\/iovs.13-12574","article-title":"Expression of neonatal Fc receptor in the eye","volume":"55","author":"Powner","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2024.101302_bib83","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.9039","article-title":"Safety and efficacy of tusamitamab ravtansine (SAR408701) in long-term treated patients with nonsquamous non\u2013small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)","volume":"40","author":"Ricordel","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.preteyeres.2024.101302_bib84","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.preteyeres.2024.101302_bib85","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.ophtha.2020.07.047","article-title":"Belantamab mafotodin-induced epithelial keratopathy masquerading myopic surgery","volume":"127","author":"Rousseau","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2024.101302_bib86","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1136\/ijgc-2022-003927","article-title":"Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study","volume":"33","author":"Santin","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.preteyeres.2024.101302_bib87","doi-asserted-by":"crossref","first-page":"S1288","DOI":"10.1016\/j.annonc.2021.08.2088","article-title":"LBA15 Primary outcome of the phase III SYD985.002\/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician's choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer","volume":"32","author":"Saura Manich","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.preteyeres.2024.101302_bib88","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/archopht.118.5.615","article-title":"Reliability and validity of the ocular surface disease Index","volume":"118","author":"Schiffman","year":"2000","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2024.101302_bib89","series-title":"Adcetris\u00ae (Brentuximab Vedotin) for Injection, for Intravenous Use","year":"2023"},{"key":"10.1016\/j.preteyeres.2024.101302_bib90","article-title":"Tivdak\u00ae (tisotumab vedotin-tftv) for injection, for intraveous use. Prescribing information","year":"2023","journal-title":"Sea"},{"key":"10.1016\/j.preteyeres.2024.101302_bib91","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.survophthal.2013.09.002","article-title":"Corneal nerves in health and disease","volume":"59","author":"Shaheen","year":"2014","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2024.101302_bib92","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.4136","article-title":"Phase Ib study of anetumab ravtansine in combination with immunotherapy or immunotherapy plus chemotherapy in mesothelin-enriched advanced pancreatic adenocarcinoma: NCI10208","volume":"40","author":"Spiliopoulou","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.preteyeres.2024.101302_bib93","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/annonc\/mdw100","article-title":"Ocular toxicities of MEK inhibitors and other targeted therapies","volume":"27","author":"Stjepanovic","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.preteyeres.2024.101302_bib94","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jconrel.2016.06.025","article-title":"Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokinetics","volume":"236","author":"Thompson","year":"2016","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.preteyeres.2024.101302_bib95","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/1078-0432.CCR-20-1067","article-title":"A phase I study of DLYE5953A, an anti-LY6E antibody covalently linked to monomethyl auristatin E, in patients with refractory solid tumors","volume":"26","author":"Tolaney","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.preteyeres.2024.101302_bib96","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3390\/antib2010113","article-title":"Antibody drug conjugates as cancer therapeutics","volume":"2","author":"Trail","year":"2013","journal-title":"Antibodies"},{"key":"10.1016\/j.preteyeres.2024.101302_bib97","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3324\/haematol.2017.168401","article-title":"A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy","volume":"103","author":"Trn\u0115n\u00fd","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.preteyeres.2024.101302_bib98","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/2040620712443076","article-title":"Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma","volume":"3","author":"Vaklavas","year":"2012","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.preteyeres.2024.101302_bib99","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41598-020-80898-7","article-title":"Ocular side effects of novel anti-cancer biological therapies","volume":"11","author":"Vishnevskia-Dai","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.preteyeres.2024.101302_bib100","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.678634","article-title":"Ocular toxicity of belantamab mafodotin, an oncological perspective of management in relapsed and refractory multiple myeloma","volume":"11","author":"Wahab","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.preteyeres.2024.101302_bib101","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/02713688908995183","article-title":"Fc receptors in corneal epithelium","volume":"8","author":"Wang","year":"1989","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.preteyeres.2024.101302_bib102","article-title":"Besponsa. Prescribing information","year":"2018","journal-title":"Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc."},{"key":"10.1016\/j.preteyeres.2024.101302_bib103","article-title":"MylotargTM (gemtuzumab ozogamicin) for injection, for intravenous use. Prescribing information","year":"2021","journal-title":"Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc."},{"key":"10.1016\/j.preteyeres.2024.101302_bib104","article-title":"Clinical benefits and safety of gemtuzumab ozogamicin in treating acute myeloid leukemia in various subgroups: an updated systematic review, meta-analysis, and network meta-analysis","volume":"12","author":"Xu","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.preteyeres.2024.101302_bib105","first-page":"13","article-title":"Corneal innervation and sensation: the eye and beyond","volume":"91","author":"Yang","year":"2018","journal-title":"Yale J. Biol. Med."},{"key":"10.1016\/j.preteyeres.2024.101302_bib106","first-page":"13","article-title":"Focus: sensory biology and pain: corneal innervation and sensation: the eye and beyond","volume":"91","author":"Yang","year":"2018","journal-title":"Yale J. Biol. Med."},{"key":"10.1016\/j.preteyeres.2024.101302_bib107","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1158\/1078-0432.CCR-22-0456","article-title":"Phase I trial of a novel anti-HER2 antibody\u2013drug conjugate, ARX788, for the treatment of HER2-positive metastatic breast cancer","volume":"28","author":"Zhang","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.preteyeres.2024.101302_bib108","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1158\/0008-5472.CAN-17-3202","article-title":"Modulation of macropinocytosis-mediated internalization decreases ocular toxicity of antibody-drug conjugates","volume":"78","author":"Zhao","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.preteyeres.2024.101302_bib109","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1158\/1535-7163.MCT-16-0710","article-title":"Inhibition of megakaryocyte differentiation by antibody-drug conjugates (ADCs) is mediated by macropinocytosis: implications for ADC-induced thrombocytopenia","volume":"16","author":"Zhao","year":"2017","journal-title":"Mol. Cancer Therapeut."}],"container-title":["Progress in Retinal and Eye Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1350946224000673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1350946224000673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T15:01:16Z","timestamp":1730991676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1350946224000673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":100,"alternative-id":["S1350946224000673"],"URL":"https:\/\/doi.org\/10.1016\/j.preteyeres.2024.101302","relation":{},"ISSN":["1350-9462"],"issn-type":[{"value":"1350-9462","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocular adverse events associated with antibody-drug conjugates used in cancer: Focus on pathophysiology and management strategies","name":"articletitle","label":"Article Title"},{"value":"Progress in Retinal and Eye Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.preteyeres.2024.101302","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101302"}}